We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
New Alliances to Support STERIS Stock Despite Macro Issues
Read MoreHide Full Article
STERIS (STE - Free Report) continues to gain from a strong rebound in procedure volumes in the United States within the Healthcare business. New acquisitions and partnerships should strengthen its product offerings. Yet macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold) currently.
Factors Driving STERIS' Growth
STERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain the equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. For the fiscal second quarter, Healthcare reported revenue growth of 9% year over year. This outperformance indicated a 12% improvement in consumable revenues and 14% growth in service revenues, with both segments posting strong organic revenue growth.
The Applied Sterilization Technologies (AST) division experienced 9% reported growth year over year in the second quarter of fiscal 2025. This performance was driven by a 6% increase in service revenues and a significant improvement in capital equipment revenues. Constant currency organic revenues in the fiscal second quarter rose in high single digits. STERIS experienced its first signs of increased bioprocessing demand. Meanwhile, global MedTech customers were stable. The company expects bioprocessing revenues to grow in the second half of fiscal 2025.
Further, STERIS frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses. In recent years, the company has made several large acquisitions. It purchased the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company or BD. The acquisition strengthens, complements and expands STERIS’ Healthcare product offerings with renowned brands like V. Mueller, Snowden-Pencer and Genesis. The company is poised for another strong fiscal year, with reported revenues from continuing operations expected to grow 6% to 7%.
Year to date, shares of STE dropped 1.7% against the industry’s 4.9% growth. However, as the company continues to experience increased bioprocessing demand, this might help the AST business to gain further momentum. Added to this, several strategic acquisitions and partnerships are expected to help the stock to witness an uptrend in the coming days.
The current macroeconomic environment across the globe has affected STERIS’ financial operations. Governments and insurance companies continue to look for ways to contain the rising cost of healthcare. This is significantly putting pressure on players in the healthcare industry, with STERIS being no exception. Increases in prices or decreases in the availability of raw materials and oil and gas have also historically impaired STERIS’ procurement of necessary materials for product manufacture, leading to an increase in production costs. In addition, economic and market volatility have been affecting the investment portfolio of STERIS’ legacy defined benefit pension plan. We are concerned that lingering macroeconomic softness might hamper STERIS’ growth.
These macroeconomic factors are also resulting in a significant escalation in the company’s operating expenses. STERIS witnessed a 0.3% year-over-year rise in selling, general and administrative expenses in the fiscal second quarter. Our model projects a 10.9% increase in the company’s selling, general and administrative expenses in fiscal 2025.
Further, with nearly 30% of the company’s revenues and costs of revenues being generated outside the United States, foreign currency exchange rate fluctuations can significantly impact its financial position, results of operations, and competitive position. For most operations, local currencies have been determined to be the functional currencies. For example, the ongoing geopolitical instability, such as Russia’s invasion of Ukraine, has negatively impacted the global and U.S. economies, leading to supply-chain disruptions, rising interest rates, volatility in capital markets and foreign currency exchange rates, and heightened cybersecurity risks. In the fiscal second quarter of 2025, the company’s revenues were negatively impacted by currency fluctuations of nearly $2.1 million.
Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 1.8% compared with the industry’s 23.1% growth in the past year. Estimates for Haemonetics’ 2025 EPS have moved 0.4% north to $4.59 in the past 30 days.
Estimates for Penumbra’s 2024 EPS have moved 8.1% north to $2.79 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 10.54%.
Estimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
New Alliances to Support STERIS Stock Despite Macro Issues
STERIS (STE - Free Report) continues to gain from a strong rebound in procedure volumes in the United States within the Healthcare business. New acquisitions and partnerships should strengthen its product offerings. Yet macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold) currently.
Factors Driving STERIS' Growth
STERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain the equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. For the fiscal second quarter, Healthcare reported revenue growth of 9% year over year. This outperformance indicated a 12% improvement in consumable revenues and 14% growth in service revenues, with both segments posting strong organic revenue growth.
The Applied Sterilization Technologies (AST) division experienced 9% reported growth year over year in the second quarter of fiscal 2025. This performance was driven by a 6% increase in service revenues and a significant improvement in capital equipment revenues. Constant currency organic revenues in the fiscal second quarter rose in high single digits. STERIS experienced its first signs of increased bioprocessing demand. Meanwhile, global MedTech customers were stable. The company expects bioprocessing revenues to grow in the second half of fiscal 2025.
Further, STERIS frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses. In recent years, the company has made several large acquisitions. It purchased the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company or BD. The acquisition strengthens, complements and expands STERIS’ Healthcare product offerings with renowned brands like V. Mueller, Snowden-Pencer and Genesis. The company is poised for another strong fiscal year, with reported revenues from continuing operations expected to grow 6% to 7%.
Year to date, shares of STE dropped 1.7% against the industry’s 4.9% growth. However, as the company continues to experience increased bioprocessing demand, this might help the AST business to gain further momentum. Added to this, several strategic acquisitions and partnerships are expected to help the stock to witness an uptrend in the coming days.
STERIS plc Price
STERIS plc price | STERIS plc Quote
Concerning Factors for STE
The current macroeconomic environment across the globe has affected STERIS’ financial operations. Governments and insurance companies continue to look for ways to contain the rising cost of healthcare. This is significantly putting pressure on players in the healthcare industry, with STERIS being no exception. Increases in prices or decreases in the availability of raw materials and oil and gas have also historically impaired STERIS’ procurement of necessary materials for product manufacture, leading to an increase in production costs. In addition, economic and market volatility have been affecting the investment portfolio of STERIS’ legacy defined benefit pension plan. We are concerned that lingering macroeconomic softness might hamper STERIS’ growth.
These macroeconomic factors are also resulting in a significant escalation in the company’s operating expenses. STERIS witnessed a 0.3% year-over-year rise in selling, general and administrative expenses in the fiscal second quarter. Our model projects a 10.9% increase in the company’s selling, general and administrative expenses in fiscal 2025.
Further, with nearly 30% of the company’s revenues and costs of revenues being generated outside the United States, foreign currency exchange rate fluctuations can significantly impact its financial position, results of operations, and competitive position. For most operations, local currencies have been determined to be the functional currencies. For example, the ongoing geopolitical instability, such as Russia’s invasion of Ukraine, has negatively impacted the global and U.S. economies, leading to supply-chain disruptions, rising interest rates, volatility in capital markets and foreign currency exchange rates, and heightened cybersecurity risks. In the fiscal second quarter of 2025, the company’s revenues were negatively impacted by currency fluctuations of nearly $2.1 million.
Key Picks
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Penumbra (PEN - Free Report) and ResMed (RMD - Free Report) . While ResMed sports a Zacks Rank #1 (Strong Buy) at present, Haemonetics and Penumbra carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 1.8% compared with the industry’s 23.1% growth in the past year. Estimates for Haemonetics’ 2025 EPS have moved 0.4% north to $4.59 in the past 30 days.
Estimates for Penumbra’s 2024 EPS have moved 8.1% north to $2.79 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 10.54%.
Estimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.